Extensive-stage small-cell lung cancer: Current management and future directions

Area of Science:

• Oncology
• Pulmonology
• Immunotherapy

Background:

• Extensive-stage small-cell lung cancer (ES-SCLC) is a refractory malignancy with rapid progression.
• Historically, treatment advancements for ES-SCLC have been limited for over three decades.

Purpose of the Study:

• To review recent research advances in the management of ES-SCLC.
• To outline current therapeutic strategies and discuss future directions for ES-SCLC treatment.

Main Methods:

• Literature review of recent studies on ES-SCLC treatments.
• Analysis of clinical trial data for immune checkpoint inhibitors, chemotherapy, and targeted agents.
• Exploration of molecular profiling and its role in personalized medicine for SCLC.

Main Results:

• Immune checkpoint inhibitors (ICIs) combined with platinum-based chemotherapy represent a significant breakthrough, establishing a new first-line standard for ES-SCLC.
• Other agents like antiangiogenic drugs, PARP inhibitors, and lurbinectedin show some benefit but have not yet led to major breakthroughs.
• Emerging strategies include targeted agents, novel chemotherapeutics, and immunotherapies, showing promise for patient treatment.

Conclusions:

• The combination of ICIs and chemotherapy has transformed ES-SCLC first-line treatment.
• Molecular subtyping of SCLC through RNA sequencing enables tailored therapeutic approaches and precision medicine.
• Continued research into novel agents and personalized strategies is crucial for advancing ES-SCLC care.